

Molecular docking analysis of *Carica papaya* Linn constituents as antiviral agent

¹Radhakrishnan, N., ²Lam, K. W. and ^{1,3*}Norhaizan, M. E.

¹Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia

²Faculty of Pharmacy, Universiti Kebangsaan Malaysia (UKM), Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia

³Laboratory of Molecular Biomedicine, Institute of Bioscience (IBS), Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia

Article history

Received: 8 August 2016
Received in revised form:
22 August 2016
Accepted: 24 August 2016

Abstract

Carica papaya (papaya) fruits are available throughout the world and it is well accepted as food or as a quasi-drug. Aqueous papaya leaves extract have been used as treatment for dengue fever. This prompted us to carry out the docking study on these nine selected ligands (phyto-constituents of papaya) which are carpaine, dehydrocarpaine I and II, cardenolide, p-coumaric acid, chlorogenic acid, caricaxanthin, violaxanthin and zeaxanthin. These phyto-constituents were evaluated on the docking behaviour of dengue serotype 3 RNA-dependent RNA polymerase (RdRp); influenza A (H1N9) virus neuraminidase (NA); chikungunya virus glycoprotein (E3-E2-E1) and chikungunya virus non-structural protein2 (nsP2) protease using Discovery Studio Version 3.1. In addition, molecular physicochemical, drug-likeness, ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) and TOPKAT (Toxicity Prediction by Komputer Assisted Technology) analyses were done. The molecular physicochemical analysis revealed that cardenolide and p-coumaric acid (2 ligands) complied with Lipinski's rule of five. Dehydrocarpaine II, cardenolide, caricaxanthin, violaxanthin and zeaxanthin all the five ligands were predicted to have plasma protein binding (PPB) effect. Docking studies and binding free energy calculations revealed that p-coumaric acid exhibited very least binding energy irrespective of its target protein. Hence, the results of this present study exhibited the potential of these nine ligands as antiviral agent.

© All Rights Reserved

Keywords

Carpaine
p-coumaric acid,
Violaxanthin
Dengue
Influenza
Chikungunya

Introduction

Carica papaya Linn is commonly known as papaya. It is well known for its food and nutritional values and moreover it is one among the popular fruits of the world. It is also called as "fruit of a common man", owing to its high nutritive value and moreover it's available for reasonable price throughout the world (Krishna *et al.*, 2008). The fruit, flower, seed, leaf, bark and root of papaya tree are known to possess many biological active compounds, in which alkaloid is an important group of interest. For example, carpaine (alkaloid) from papaya leaf has been shown to have antiprotozoal, anthelmintic, antiplasmodial (Julianti *et al.*, 2014) and antithrombocytopenic activity (Zunjar *et al.*, 2016). Similarly, danielone from papaya fruit has been reported to have antifungal activity against *Colletotrichum gloeosporioides* (Yogiraj *et al.*, 2014).

Various parts of papaya have been utilized in traditional medicine in different parts of the world.

For instance, daily consumption of green papaya leaves and as well as herbal infusion have been reported in some areas of Indonesia as means for preventing malaria disease (Julianti *et al.*, 2014). Similarly aqueous papaya leaves extract have been used as treatment for dengue fever, which help the patient to increase platelets, white blood cells and neutrophil counts (Ahmad *et al.*, 2011). In other report, flavonoid from papaya has been shown to inhibit viral non structural 2B and 3 (NS2B-NS3) protease complex and thereby prevents dengue 2 viral (DENV-2) assembly using molecular docking study (Senthilvel *et al.*, 2013). This prompted us to carry out the docking study on these nine selected ligands (phyto-constituents of papaya) which are carpaine, dehydrocarpaine I and II, cardenolide, p-coumaric acid, chlorogenic acid, caricaxanthin, violaxanthin and zeaxanthin. These phyto-constituents were evaluated on the docking behaviour of dengue serotype 3 RNA-dependent RNA polymerase (RdRp); influenza A (H1N9) virus neuraminidase

*Corresponding author.
Email: nhaizan@upm.edu.my

(NA); chikungunya virus glycoprotein (E3-E2-E1) and chikungunya virus non-structural protein2 (nsP2) protease with investigation on the enzymes putative binding sites using Discovery Studio Version 3.1. Therefore, the present study aims to determine the nine *Carica papaya* phyto-constituents as antiviral agent especially against dengue, influenza and chikungunya viruses using molecular docking method.

Materials and Methods

Ligand preparation

Chemical structures of the ligands i) caripaine (CID442630); ii) dehydrocaripaine I (HMDB30271); iii) dehydrocaripaine II (HMDB30273); iv) cardenolide (Chempid ID19954501); v) p-coumaric acid (CID637542); vi) chlorogenic acid (Chempid ID1405788); vii) caricaxanthin (Chempid ID4444647); viii) violaxanthin (Chempid ID395237) and ix) zeaxanthin (Chempid ID444421) were retrieved from PubMed (www.pubmed.com) compound, human metabolome (www.hmdb.ca/metabolites) and Chempid (www.chemspider.com) compound database respectively.

Target protein identification and preparation

The three dimensional structures of the dengue RNA-dependent RNA polymerase (RdRp) (PDB ID: 3VWS with resolution of 2.1 Å), influenza neuraminidase (PDB ID: 1L7F with resolution of 1.8 Å), chikungunya glycoprotein (PDB ID: 3N44 with resolution of 2.35 Å) and chikungunya nsP2 protease (PDB ID: 3TRK with resolution of 2.4 Å) were obtained from the Research Collaborator for Structural Bioinformatics (RCSB) Protein Data Bank (Anonymous, www.rcsb.org). A chain of all of the proteins (except for chikungunya glycoprotein, where A, B and F) was pre-processed separately by deleting ligand, as well as the crystallographically observed water molecules (water without hydrogen bonds).

Molecular descriptors calculation

Molinspiration online database was used for the nine selected ligands to calculate thirteen descriptors (www.molinspiration.com) which are log P, polar surface area, molecular weight, number of atoms, number of O or N, number of OH or NH, number of rotatable bonds, volume, drug likeness including G protein coupled receptors (GPCR) ligand, ion channel modulator, kinase inhibitor and nuclear receptor ligand, and the number of violations to Lipinski's rule.

ADMET and TOPKAT analysis

Both of ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) and TOPKAT (Toxicity Prediction by Komputer Assisted Technology) tests were performed using Discovery Studio® 3.1 (Accelrys, San Diego, USA). ADMET analysis was performed using human intestinal absorption (HIA), aqueous solubility (AS), blood brain barrier (BBB), cytochrome P450 2D6 (CYP2D6), plasma protein binding (PPB) and hepatotoxicity (HT) descriptors. As for the TOPKAT analysis, aerobic biodegradability (AB), Ames mutagenicity (AM), ocular irritancy (OI), skin irritancy (SI), skin sensitization (SS) and oral toxicity in rat (LD50 in g/Kg of body weight) descriptors were used.

Docking studies

Docking studies were carried out on the crystal structures of dengue RNA-dependent RNA polymerase (RdRp), influenza neuraminidase, chikungunya glycoprotein and chikungunya nsP2 protease retrieved from Protein Data Bank using the CDOCKER protocol under the protein-ligand interaction section in Discovery Studio® 3.1 (Accelrys, San Diego, USA). In general, CDOCKER is a grid-based molecular docking method that employs CHARMM force fields. A protein was firstly held rigid while the ligands were allowed to flex during the refinement. Two hundred random ligand conformations were then generated from the initial ligand structure through high temperature molecular dynamics followed by random rotations, refinement by grid-based (GRID I) simulated annealing, and a final grid-based or full force field minimisation (Wu *et al.*, 2003). In this experiment, the ligand was heated to a temperature of 700 K in 2000 steps and the cooling steps were set in 5000 steps to 300 K with the grid extension set to 10 Å. Hydrogen atoms were added to the structures and all ionisable residues were set at their default protonation state at a neutral pH. For each ligand, top ten ligand binding poses were ranked according to their CDOCKER energies, and the predicted binding interactions were then analysed from which the best among the ten ligand binding poses was chosen and carried out *in situ* ligand minimization using standard protocol.

Results

Molecular descriptors analysis

Violation of zero will be the main target compound which was observed for cardenolide and p-coumaric acid suggesting that these compounds complied very well with the Lipinski's rule of five. However,

Table 1. Molecular physicochemical descriptors analysis of nine ligands using Molinspiration online software tool

Ligand	Log A ^a	TPSA ^a	Nato ms ^e	MW ^d	noN *	nOH NH ^f	Nviolations *	Nrotb ^h	Volume ⁱ
Carpaine	6.40	76.7	34	478.7	6	2	1	0	497.4
Dehydrocarpaine-I	6.60	77.0	34	476.7	6	1	1	0	491.4
Dehydrocarpaine-II	6.79	77.3	34	474.7	6	0	1	0	485.4
Cardenolide	4.98	26.3	25	342.5	2	0	0	1	348.9
p-Coumaric acid	1.43	57.5	12	164.2	3	2	0	2	146.5
Chlorogenic acid	-0.45	164.7	25	354.3	9	6	1	5	296.3
Caricaxanthin	9.64	20.2	41	552.9	1	1	2	10	600.0
Violaxanthin	9.00	65.5	44	600.9	4	2	2	10	615.5
Zeaxanthin	9.40	40.5	42	568.9	2	2	2	10	608.0

^a Octanol-Water partition coefficient, ^b Polar surface area, ^c Number of non hydrogen atoms, ^d Molecular weight, ^e Number of hydrogen bond acceptors [O and N atoms], ^f Number of hydrogen bond donors [OH and NH groups], ^g Number of Rule of 5 violations, ^h Number of rotatable bonds, ⁱ Molecular volume.

Table 2. Drug-likeness property analysis of 9 ligands using Molinspiration online software tool

Ligand	GPCR [*] ligand	Ion channel modulator	Kinase inhibitor	Nuclear receptor ligand	Protease inhibitor	Enzyme inhibitor
Carpaine	0.11	-0.00	-0.12	-0.12	0.16	0.07
Dehydrocarpaine-I	0.08	-0.03	-0.24	-0.21	0.01	0.07
Dehydrocarpaine-II	0.03	-0.01	-0.20	-0.04	-0.05	0.09
Cardenolide	0.25	0.22	-0.40	0.72	0.14	0.50
p-Coumaric acid	-0.56	-0.26	-0.91	-0.12	-0.87	-0.15
Chlorogenic acid	0.29	0.14	-0.00	0.74	0.27	0.62
Caricaxanthin	-0.03	-0.25	-0.20	0.49	0.02	0.24
Violaxanthin	-0.06	-0.56	-0.35	0.13	0.08	-0.03
Zeaxanthin	-0.08	-0.36	-0.24	0.35	0.01	0.13

*GPCR- G Protein coupled receptors

carpaine, dehydrocarpaine I and II and chlorogenic acid showed one violation and caricaxanthin, violaxanthin and zeaxanthin showed two violations as shown in Table 1. Similarly in the present study only one ligand (cardenolide) showed active score (>0) towards all the six descriptors (except kinase inhibitor), whereas rest of ligands exhibited active to moderate active scores. Interestingly none of the ligand that shown inactive score (<-5.0), as shown in the Table 2.

ADMET and TOPKAT analysis

Table 3 shows the ADMET profile of the nine ligands, wherein cardenolide showed very high blood brain barrier (BBB) penetration effect compared to that of other ligands. Dehydrocarpaine II, cardenolide, caricaxanthin, violaxanthin and zeaxanthin all the five ligands were predicted to have plasma protein binding (PPB) effect. The toxicity profile of nine ligands as depicted in Table 4 all the ligands exhibited degradable nature towards aerobic biodegradability

Table 3. ADMET analysis of nine ligands

Ligand	HIA			AS			BBB		PPB	CYP2D6	HT
	PSA	ALog P8	L*	Log(SW)	L**	Log BB	L***	Predication			
Carpaine	78.08	6.11	2	-7.57	1	0	4	F	F	F	
Dehydrocarpaine-I	76.60	6.08	1	-7.26	1	0	4	F	F	F	
Dehydrocarpaine-II	75.11	6.05	1	-6.95	1	0	4	T	F	F	
Cardenolide	26.23	4.94	0	-6.83	1	0.96	0	T	F	F	
p-Coumaric acid	58.93	1.68	0	-1.38	4	-0.57	3	F	F	F	
Chlorogenic acid	168.4	-0.34	3	-1.26	4	0	4	F	F	F	
Caricaxanthin	20.81	10.76	3	-7.96	1	0	4	T	F	F	
Violaxanthin	59.49	7.00	3	-4.65	2	0	4	T	F	F	
Zeaxanthin	41.63	9.52	3	-6.20	1	0	4	T	F	F	

HIA-Human intestinal absorption, AS- Aqueous solubility, BBB-Blood brain barrier, PPB-Plasma protein binding, CYP2D6- cytochrome P450 2D6, HT-hepatotoxicity, L-Level, F-False and T-True.] *(0-good; 1-moderate; 2-poor and 3-very poor) ;**(0-extremely low; 1-very low; 2-low; 3-good; 4-optimal; 5-too soluble and 6-warning);***(0-very high penetrate; 1-high; 2-medium; 3-low and 4-undefined)

Table 4. Toxicity prediction analysis of nine ligands

Ligand	AB*	AM**	OI#	SI##	SS*	Oral toxicity ▲
Carpaine	Degradable	Non-mutagen	Irritant	Irritant	Non-sensitizer	0.58
Dehydrocarpaine-I	Degradable	Non-mutagen	Irritant	Irritant	Non-sensitizer	0.23
Dehydrocarpaine-II	Degradable	Non-mutagen	Irritant	Irritant	Non-sensitizer	0.40
Cardenolide	Degradable	Non-mutagen	Irritant	Irritant	Sensitizer	2.90
p-Coumaric acid	Degradable	Non-mutagen	Irritant	Non-irritant	Sensitizer	1.42
Chlorogenic acid	Degradable	Non-mutagen	Irritant	Non-irritant	Non-sensitizer	1.48
Caricaxanthin	Degradable	Non-mutagen	Irritant	Irritant	Sensitizer	3.97
Violaxanthin	Degradable	Non-mutagen	Irritant	Irritant	Sensitizer	ND*
Zeaxanthin	Degradable	Non-mutagen	Irritant	Irritant	Sensitizer	4.56

AB*- Aerobic biodegradability; AM**- Ames mutagenicity; OI#- Ocular irritancy; SI##- Skin irritancy; SS*- Skin sensitization and Oral toxicity▲- Oral toxicity in rat (LD₅₀ in g/Kg of body weight-rat)

effect. All of the ligands were predicted to have ocular irritancy effect in human.

Molecular docking study

The docking studies and binding free energy calculations reported in Table 5A show that violaxanthin had the highest interaction energy (-59.17 kcal/mol) with that of dengue RNA-dependent RNA polymerase (RdRp). In contrast, p-coumaric acid showed the least interaction energy (-22.39 kcal/mol) compared to other ligands. Interestingly

four ligands (carpaine, dehydrocarpaine I and II and cardenolide) exhibited interaction with Thr413 amino acid residue of dengue RNA-dependent RNA polymerase (RdRp) as shown in Table 5A. As for the docking studies and binding free energy calculations with influenza neuraminidase, violaxanthin exhibited the highest interaction energy (-53.54 kcal/mol) as shown in Table 5B. However, in the present study four ligands (carpaine, dehydrocarpaine I and II and cardenolide) fail to dock with influenza neuraminidase. Moreover, two ligands (violaxanthin

Table 5 A. The interaction energy analysis of nine ligands with that of dengue serotype 3 RNA-dependent RNA polymerase (RdRp) using Discovery Studio® 3.1

Ligand name	-cDocker interaction energy (kcal/mol)	Interaction amino acid residue	Bond distance (Å)
Carpaine	54.83	Thr413	2.3
		Asn492	1.9
Dehydrocarpaine-I	50.70	Lys401	2.3
		Thr413	1.9
Dehydrocarpaine-II	50.00	Thr413	2.4
		Asn492	1.1
		Gly604	2.0
Cardenolide	35.72	Thr413	1.3
p-Coumaric acid	22.39	Val603*	2.9
		Gly604	1.9
		Thr605	2.1
		Tyr606	2.2
Chlorogenic acid	38.09	Lys401*	5.8
		Ser600	2.0
		Gly602	1.1
		Thr605	2.1 and 2.3
Caricaxanthin	56.84	Asp663	1.7
Violaxanthin	59.17	Arg792	2.0
		Ser796	1.8
		Ile797	1.6
		His801	2.3
Zeaxanthin	57.04	Ser600	1.7
		Asn609	2.2

▪ Pi-Sigma interaction, * Pi+ interaction

Table 5 B. The interaction energy analysis of nine ligands with that of influenza A (H1N9) virus neuraminidase (NA) using Discovery Studio® 3.1

Ligand name	-cDocker interaction energy (kcal/mol)	Interaction amino acid residue	Bond distance (Å)
Carpaine	F ⁻	-	-
Dehydrocarpaine-I	F ⁻	-	-
Dehydrocarpaine-II	F ⁻	-	-
Cardenolide	F ⁻	-	-
p-Coumaric acid	25.80	Arg292	1.9
		Arg371	1.7
Chlorogenic acid	43.00	Arg152	2.2
		Asn221	2.0
		Arg224 [◊]	6.2
		Ser245	1.7
		Thr247	2.2
		Arg292	2.1
Tyr406	2.3		
Caricaxanthin	51.81	No interaction	-
Violaxanthin	53.54	Glu227	1.9
Zeaxanthin	51.43	Glu227	1.8

*F- Fails to dock, ◊ +-Pi interaction

and zeaxanthin) showed interaction with Glu227 amino acid residue of influenza neuraminidase. The docking studies and binding free energy calculations reported in Table 5C show that violaxanthin had the

Table 5 C. The interaction energy analysis of nine ligands with that of chikungunya virus glycoprotein (E3-E2-E1) using Discovery Studio® 3.1

Ligand name	-cDocker interaction energy (kcal/mol)	Interaction amino acid residue	Bond distance (Å)
Carpaine	F ⁻	-	-
Dehydrocarpaine-I	F ⁻	-	-
Dehydrocarpaine-II	F ⁻	-	-
Cardenolide	F ⁻	-	-
p-Coumaric acid	22.52	ValB135	1.3 and 2.3
		ProB152	2.3
		LysF181	1.7
		ArgF247 [◊]	4.7
Chlorogenic acid	F ⁻	-	-
Caricaxanthin	48.63	AsnB263	2.1
Violaxanthin	52.82	AsnB263	1.3
Zeaxanthin	52.03	AsnB263	1.1

F⁻ - Fails to dock, ◊ +-Pi interaction

Table 5 D. The interaction energy analysis of nine ligands with that of chikungunya virus non-structural protein2 (nsP2) protease using Discovery Studio® 3.1

Ligand name	-cDocker interaction energy (kcal/mol)	Interaction amino acid residue	Bond distance (Å)
Carpaine	F ⁻	-	-
Dehydrocarpaine-I	F ⁻	-	-
Dehydrocarpaine-II	F ⁻	-	-
Cardenolide	F ⁻	-	-
p-Coumaric acid	22.31	Lys1239	2.0
Chlorogenic acid	46.82	Lys1042	2.1
		Glu1043	1.4
		Lys1045	0.64 and 1.0
		Phe1225	1.8 and 2.0
Lys1239 [◊]	3.8		
Caricaxanthin	50.79	No interaction	-
Violaxanthin	53.38	No interaction	-
Zeaxanthin	53.93	No interaction	-

F⁻ - Fails to dock, ◊ +-Pi interaction

highest interaction energy (-52.82 kcal/mol) with that of chikungunya glycoprotein. However, in the present study five ligands (carpaine, dehydrocarpaine I and II, cardenolide and chlorogenic acid) fail to dock with chikungunya glycoprotein. Interestingly three ligands (caricaxanthin, violaxanthin and zeaxanthin) exhibited interaction with Asn263 amino acid residue of chikungunya glycoprotein B chain. As for the docking studies and binding free energy calculations

with chikungunya nsP2 protease, p-coumaric acid showed the least interaction energy (-22.31 kcal/mol) as shown in Table 5D. However, in the present study four ligands (carpaine, dehydrocarpaine I and II and cardenolide) fail to dock with chikungunya nsP2 protease. Two ligands (p-coumaric acid and chlorogenic acid) exhibited interaction with Lys1239 amino acid residue of chikungunya nsP2 protease as shown in Table 5D.

Discussion

Natural products have been serving as a main source of potential drugs. Recently, four natural product derivatives have been approved as an antiviral drug out of 138 drugs approved up to 2014 (Newman and Cragg, 2016) and which actually encourages more studies and research in natural product drug discovery programme. Interestingly, some proteolytic viral enzymes namely viral polymerase, integrase and reverse transcriptase serves as target for developing new antiviral agents. Because these enzymes, plays vital role in viral replication and assembly of the mature viral particle (Mishra *et al.*, 2013). Searching for available foods/food products is still another wise strategy to develop specific inhibitors against these viral enzymes. *Carica papaya* fruits are available throughout the world and it is well accepted as food or as a quasi-drug (Kovendan *et al.*, 2012). In the present study, we carried out molecular docking analysis on *Carica papaya* constituents as antiviral agent against i) dengue serotype 3 RNA-dependent RNA polymerase (RdRp); ii) influenza A (H1N9) virus neuraminidase (NA); iii) chikungunya virus glycoprotein (E3-E2-E1) and iv) chikungunya virus non-structural protein2 (nsP2) protease. Bhatt and co-workers (2013) reported that over half (50%) of the world's population is at high risk for infection by dengue virus. Reiner and co-workers (2014) reported that force of infection (FoI) in the case of dengue virus (DENV) has been observed high for dengue serotype 3 and 4, when compare to that of dengue serotype 1 and 2. RNA-dependent RNA polymerase (RdRp) is an enzyme which catalyzes the replication of RNA from an RNA template. It is a vital protein encoded in the genomes of all RNA containing viruses including Dengue virus and its activity is essential for maintaining viral cycle and replication (Bhattacharya *et al.*, 2008). In general, RdRp enzymes family had three conserved sub-domains such as palm, fingers and thumb. RdRp from dengue virus serotype 3 (DENV-3) has been reported to be new target for developing novel antiviral compounds against dengue fever (Hansen *et al.*, 1997 and Ariza

et al., 2014). In the present study, all nine ligands had docked well with RNA-dependent RNA polymerase (RdRp) of dengue serotype 3 viral enzyme. Yogiraj and co-workers (2014) had summarized four pilot studies on use of *Carica papaya* as therapeutic agent for dengue fever management. Similarly, Senthilvel and co-workers (2013) had reported that both p-coumaric acid and chlorogenic acid inhibits viral non structural 2B and 3 (NS2B-NS3) protease complex. The two above mentioned reports were in good agreement with the present study.

Influenza is commonly called as flu, which is a serious infectious disease caused by influenza virus. At present much attention has been gained among the researchers to develop inhibitors of influenza neuraminidase (NA), because it serves as a main drug target for both prophylaxis and treatment for influenza infection. Shaukat and co-workers (2011) reported that papaya leaves extract at low concentrations (2 to 8 µg/ml) fails to inhibit influenza (H7N3) virus replication. Similarly in the present study three papaya alkaloids (carpaine, dehydrocarpaine I and II) fail to dock with influenza neuraminidase (NA). Chlorogenic acid has been reported to inhibit influenza A (H5N1) virus neuraminidase (Luo *et al.*, 2011) and influenza A (H7N9) virus neuraminidase respectively (Liu *et al.*, 2015). The p-coumaric acid has been reported to have anti-influenza viral activities in mice model, by prolonging survival rates and reducing virus titers in bronchoalveolar lavage (BAL) fluids (Pie *et al.*, 2016). The above mentioned reports were in good agreement with the present study.

Chikungunya is an infectious disease caused by chikungunya virus. *Aedes albopictus* and *Aedes aegypti* are two vectors responsible for chikungunya virus transmission. Kovendan and co-workers (2012) reported that *Carica papaya* methanolic leaf extract has shown good larvicidal and pupicidal activity against the chikungunya vector (*Aedes aegypti*). Chlorogenic acid has been reported to have antiviral activity against chikungunya virus (Buhner, 2013).

Conclusion

In the present study, it was found that three ligands (caricaxanthin, violaxanthin and zeaxanthin) has the potential to dock with all the four targeted proteins, whereas four ligands (carpaine, dehydrocarpaine I and II and cardenolide) failed to dock and bind with the three targeted proteins. Interestingly all the nine ligands showed the potential to dock with dengue serotype 3 RNA-dependent RNA polymerase (RdRp), which again demonstrate the use of papaya

as therapeutic agent for dengue fever management. Hence, it is strongly suggested that the results of this present study has paved better understanding of these nine ligands of *Carica papaya* Linn as potential antiviral agent.

Acknowledgement

The author (R.N) would like to thank the Research Management Center (RMC) of Universiti Putra Malaysia (UPM) for the Post-Doctoral financial support.

References

- Ahmad, N., Fazal, H., Ayaz, M., Abbasi, B.H., Mohammad, I. and Fazal, L. 2011. Dengue fever treatment with *Carica papaya* leaves extracts. *Asian Pacific Journal of Tropical Biomedicine* 1: 330-333.
- Ariza, L.L.G., Ramirez, G.A.T., Hernández, H.F.C., Sanabria, L.P. and Osorio, J.C.C. 2014. Molecular cloning, modeling and docking with curcumin of the dengue virus 2 NS5 polymerase domain. In Castillo, L.F., Cristancho, M., Isaza, G., Pinzon, A. and Rodriguez, J.M.C (Eds). *Proceedings of the 2nd Colombian Congress on Computational Biology and Bioinformatics (CCBCOL)*, p. 273-278. Switzerland: Springer International Publication.
- Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., Drake, J.M., Brownstein, J.S., Hoen, A.G., Sankoh, O. and Myers, M.F. 2013. The global distribution and burden of dengue. *Nature* 496: 504-507.
- Bhattacharya, D., Hoover, S., Falk, S.P., Weisblum, B., Vestling, M. and Striker, R. 2008. Phosphorylation of yellow fever virus NS5 alters methyltransferase activity. *Virology* 380: 276-284.
- Buhner, S.H. 2013. Herbal antivirals. In Nancy Ringer (Ed). *Herbal antivirals: Natural remedies for emerging and resistant viral infections*, p.160. Massachusetts: Storey Publication.
- Hansen, J.L., Long, A.M. and Schultz, S.C. 1997. Structure of the RNA-dependent RNA polymerase of poliovirus. *Structure* 5: 1109-1122.
- Julianti, T., Oufir, M. and Hamburger, M. 2014. Quantification of the antiplasmodial alkaloid carpaine in papaya (*Carica papaya*) leaves. *Planta Medica* 80: 1138-1142.
- Kovendan, K., Murugan, K., Kumar, A.N., Vincent, S. and Hwang, J.S. 2012. Bioefficacy of larvicidal and pupicidal properties of *Carica papaya* (Caricaceae) leaf extract and bacterial insecticide, spinosad, against chikungunya vector, *Aedes aegypti* (Diptera: Culicidae). *Parasitology Research* 110: 669-678.
- Krishna, K.L., Paridhavi, M. and Patel, J.A. 2008. Review on nutritional, medicinal and pharmacological properties of Papaya (*Carica papaya* Linn.). *Natural Product Radiance* 7: 364-373.
- Liu, Z., Zhao, J., Li, W., Wang, X., Xu, J., Xie, J., Tao, K., Shen, L. and Zhang, R. 2015. Molecular docking of potential inhibitors for influenza H7N9. *Computational and Mathematical methods in Medicine* 2015: 1-8 (Article ID 480764).
- Luo, H.J., Wang, J.Z., Chen, J.F. and Zou, K. 2011. Docking study on chlorogenic acid as a potential H5N1 influenza A virus neuraminidase inhibitor. *Medicinal Chemistry Research* 20: 554-557.
- Mishra, K.P., Sharma, N., Diwaker, D., Ganju, L. and Singh, S.B. 2013. Plant derived antivirals: A potential source of drug development. *Journal of Virology and Antiviral Research* 2: 2-9.
- Newman, D.J. and Cragg, G.M. 2016. Natural products as sources of new drugs from 1981 to 2014. *Journal of Natural Products* 79: 629-661.
- Pei, K., Ou, J., Huang, J. and Ou, S. 2016. p-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities. *Journal of the Science of Food and Agriculture* 96: 2952-2962.
- Reiner, R.C., Stoddard, S.T., Forshey, B.M., King, A.A., Ellis, A.M., Lloyd, A.L., Long, K.C., Rocha, C., Vilcarromero, S., Astete, H. and Bazan, I. 2014. Time-varying, serotype-specific force of infection of dengue virus. *Proceedings of the National Academy of Sciences* 111: E2694-E2702.
- Senthilvel, P., Lavanya, P., Kumar, K.M., Swetha, R., Anitha, P., Bag, S., Sarveswari, S., Vijayakumar, V., Ramaiah, S. and Anbarasu, A. 2013. Flavonoid from *Carica papaya* inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly. *Bioinformation* 9: 889-895.
- Shaukat, T.M., Ashraf, M., Omer, M.O., Rasheed, M.A., Muhammad, K., Shaukat, T.M., Younus, M. and Shahzad, M.K. 2011. Comparative efficacy of various antiviral agents against avian influenza virus (Type H7N3/Pakistan/2003). *Pakistan Journal of Zoology* 43: 849-854.
- Wu, G., Robertson, D.H., Brooks, C.L. and Vieth, M. 2003. Detailed analysis of grid-based molecular docking: A case study of CDOCKER—A CHARMM-based MD docking algorithm. *Journal of Computational Chemistry* 24: 1549-1562.
- Yogiraj, V., Goyal, P.K., Chauhan, C.S., Goyal, A. and Vyas, B. 2014. *Carica papaya* Linn: An Overview. *International Journal of Herbal Medicine* 2: 01-08.
- Zunjar, V., Dash, R.P., Jivrajani, M., Trivedi, B. and Nivsarkar, M. 2016. Antithrombocytopenic activity of carpaine and alkaloidal extract of *Carica papaya* Linn. leaves in busulfan induced thrombocytopenic wistar rats. *Journal of Ethnopharmacology* 181: 20-25.